Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 900 participants.
Also called NCT04806893
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 900 participants
- Registry
-
NCT04806893
-
- Other papers using this trial's data
- Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, India, Israel
- Registry status
- Unknown status
Technical summary
Registry record NCT04806893. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2023-11-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction
- Acronym
- LIBerate-HR
- Condition
- Cardiovascular Risk Factor
- Condition
- Cardiovascular Diseases
- Condition
- Cardiovascular Stroke
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- lerodalcibep
- Intervention (Other)
- Placebo
- Lead sponsor
- LIB Therapeutics LLC
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct04806893- Content hash
f27cd7839cdd39da3b09b47d0ad64e51a2d216283f694ae9fb9d686a79dbfa3d